Topeka's Cotton O'Neil is using a new, early diagnosis tool to test new Alzheimer's treatments.

In recent years, research into cannabis and its main psychoactive ingredient, Δ⁹-tetrahydrocannabinol (THC), has unearthed ...

Highlights from CTAD 2025 include GLP-1 agonist data, p-tau217 biomarker utility, subcutaneous lecanemab trials, and racial disparities in trial enrollment.

Chronic traumatic encephalopathy has long been discussed as a possible driver of dementia, but proving that link has been ...

Researchers at Emory University have identified effective, community-driven strategies to increase participation by ...

From Science.org. "T3D Therapeutics alleges that contract researchers delivered “medically impossible” results on its candidate drug. In 2023, the drug ...

A once-a-day pill that helps slow down the course of Alzheimer’s disease is a step closer to becoming a reality in a major ...

THC plus a common anti-inflammatory drug show promise.

The finger-prick blood test employs a plasma separation card, designed to cut costs and simplify testing procedures.

Anavex (AVXL) blarcamesine faces uncertain FDA path in early Alzheimer’s; Phase 3 may be needed. Read here a detailed ...

A study by a Taiwanese doctor found a link between having too little cholesterol in a person’s diet and increased risk of dementia, Show Chwan Memorial Hospital said. The research, which utilized a ...

The largest study of its kind from the Boston University CTE Center reveals that chronic traumatic encephalopathy (CTE) ...